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 1 
Prospective evaluation of the utility of crossmatching prior to first AB matched 1 
transfusion in cats: 101 cases 2 
 3 
Objectives: To: 1) assess the frequency of crossmatch incompatibility in naïve feline blood 4 
transfusion recipients using two crossmatching methods, 2) measure the effect of 5 
crossmatch incompatibility on packed cell volume increase following transfusion,  3) 6 
assess the frequency of acute transfusion reactions and errors in blood transfusions in cats 7 
and 4) assess the impact of crossmatch incompatibility on the likelihood of transfusion 8 
reactions. 9 
Methods: Cats being administered a first AB-matched transfusion in a veterinary teaching 10 
hospital were prospectively recruited for this observational study. Major and minor 11 
crossmatching were performed using a slide agglutination method and a commercial test.  12 
Packed cell volume increase at 12 hours post transfusion relative to the mass of red blood 13 
cells given per recipient bodyweight (ΔPCVnorm) and occurrence of transfusion reactions 14 
were recorded. 15 
Results: 101 cats were recruited. Crossmatch incompatibility was common when using the 16 
slide agglutination method (27% and 10% major and minor incompatibility, respectively), 17 
 2 
but less common with the commercial test (major and minor incompatibility both 4%).  18 
Crossmatch incompatibility  (with any method) was not associated with decreased 19 
ΔPCVnorm. Transfusion reactions occurred in 20 cats, most commonly febrile non-20 
haemolytic transfusion reactions (n=9) and haemolytic transfusion reactions (n=7).  The 21 
commercial test appeared to be most specific for predicting haemolytic transfusion 22 
reactions.   23 
 24 
Conclusions and clinical relevance: Transfusion reactions were fairly common but were 25 
not associated with increased mortality.  Use of crossmatch compatible blood did not lead 26 
to a greater increase in packed cell volume at 12 hours but the commercial test may 27 
predict a haemolytic transfusion reaction.   28 
 29 
Key words: Blood type, Transfusion reaction, Mik, Packed red blood cells, whole blood, 30 






It is well recognised that recipients of feline whole blood (WB) or packed red blood cells 36 
(pRBCs) need to be administered AB type-matched products (Giger and Akol 1990, 37 
Barfield and Adamantos 2011, Giger, 2014).  There is also general consensus that 38 
crossmatching should be performed prior to a subsequent transfusion of red blood cell 39 
(RBC) containing products 3-5 days after the first transfusion of a blood product (Jagodich 40 
and Holowaychuk 2016).  However, there has been debate about the necessity to perform 41 
crossmatching prior to first transfusion in cats being administered AB matched blood 42 
(McClosky et al 2018; Sylvane et al 2018; Tasker et al 2014; Weltman et al 2014; Weinstein 43 
et al 2007). Crossmatching prior to first transfusion allows detection of serological 44 
incompatibility between the donor and recipient resulting from pre-formed antibodies 45 
against non-AB erythrocyte antigens. A compatible crossmatch result should decrease the 46 
likelihood of a haemolytic transfusion reaction (HTR).  Although this was initially a 47 
theoretical concern in cats, Weinstein et al (2007) reported a novel feline non-AB RBC 48 
antigen, Mik, and described 3 cats which had crossmatch findings consistent with naturally 49 
occurring anti-Mik antibodies.   A retrospective study suggested that crossmatched feline 50 
blood was more efficacious in raising recipient packed cell volume (PCV) than non-51 
 4 
crossmatched blood and this was postulated to be due to pre-existing recipient antibodies 52 
to Mik and possibly other non-AB erythrocyte antigens (Weltman et al 2014).  However, a 53 
recent prospective randomised trial compared administration of non-crossmatched and 54 
crossmatched pRBCs to cats (with 24 cats in each group) and found no difference in PCV 55 
increase or the rate of transfusion reaction between the groups (Sylvane et al 2018).  A 56 
retrospective study of 300 cats also found no difference in PCV increase but noted an 57 
increased rate of febrile non-haemolytic transfusion reactions (FNHTR) in the cats 58 
administered non-crossmatched pRBCs (McClosky et al 2018).   59 
 60 
Complications and errors during blood product administration, alongside the frequency 61 
and types of transfusion reaction, are recorded in human haemovigilance monitoring 62 
schemes (Poles et al 2018).  This allows repeated problems to be identified and possible 63 
solutions devised.  Clinical governance is a developing area in veterinary medicine, but a 64 
prospective assessment of the frequency and type of transfusion reactions, complications 65 
and errors in administration of blood products has not been reported before to the 66 
authors’ knowledge.   67 
 68 
 5 
The aims of this study were therefore to:  1) assess the frequency of crossmatch 69 
incompatibility in a large cohort of naïve feline blood transfusion recipients, 2) compare 70 
the results of a commercially available feline crossmatch kit with crossmatches performed 71 
by a clinical laboratory, 3) assess the effect of crossmatch incompatibility on the change in 72 
PCV seen post feline blood donation and 4) assess the frequency of acute transfusion 73 
reactions, complications and errors in cats receiving crossmatch compatible and non-74 
crossmatch compatible blood transfusions. 75 
 76 
Materials and methods 77 
This was a prospective observational study performed at a veterinary  teaching hospital 78 
aiming to recruit 100 cats receiving either a fresh WB or stored pRBC transfusion that had 79 
not previously received a RBC product.  Informed consent for participation in the study 80 
was obtained from both recipient and donor owners and the study was approved by the 81 
hospital Clinical Research Ethical Review Board.  Cats were blood typed using ethylene 82 
diamine tetraacetic acid (EDTA) anticoagulated blood and a commercially available kitA and 83 
AB type-matched blood was administered. All donors were healthy and were checked 84 
prior to each donation for feline leukaemia virus antigen and feline immunodeficiency 85 
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virus antibodies.  Blood anticoagulated in EDTA was submitted for polymerase chain 86 
reactions to detect DNA from Candidatus Mycoplasma hemominutium, Mycoplasma 87 
hemofelis and Candidatus Mycoplasma turicensis annually.  Blood was obtained prior to 88 
transfusion from the recipient and also from the donor if fresh whole blood was 89 
administered, or if stored pRBCs were used, then a crossmatch segment was obtained.   A 90 
major and a minor crossmatch (minorly modified versions of those described by Abrams-91 
Ogg, 2016) were performed by trained personnel (hereafter referred to as the laboratory 92 
method) as follows.  Recipient and donor blood samples were spun at 664 x G for 5 93 
minutes and plasma and the erythrocyte pellet were then separated. The erythrocytes 94 
were washed using an automated cell washing instrumentB and a 2% erythrocyte 95 
suspension was made using 980 µL of sterile saline and 20 µL of washed erythrocytes. Two 96 
drops of recipient plasma and 2 drops of donor erythrocyte suspension were placed and 97 
gently mixed in an Eppendorf tubeC for the major crossmatch. Two drops of donor plasma 98 
and 2 drops of recipient erythrocyte suspension were placed and gently mixed in an 99 
Eppendorf tube for the minor crossmatch.  Control tests (whereby donor plasma and 100 
donor erythrocyte suspension and recipient plasma and recipient erythrocyte suspension 101 
were mixed) were also performed.  The solutions of plasma and RBC were incubated at 102 
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room temperature for 30 minutes. The solutions were then resuspended via tube 103 
inversion and a small drop (~10 µL) of the suspension was placed onto a slide and 104 
immediately examined under the microscope at x10 and x20 objectives. Any sign of 105 
agglutination was then recorded as a positive agglutination for that crossmatch.  If the 106 
recipient control was agglutinating then an agglutinating minor crossmatch was deemed 107 
uninterpretable.  If the donor control was agglutinating then an agglutinating major 108 
crossmatch was deemed uninterpretable.   A commercially available crossmatch kitD was 109 
also used to assess major and minor crossmatch compatibility.  A crossmatch was deemed 110 
incompatible if a line of cells was present on the top of the serum gel.  Crossmatches were 111 
not routinely performed prior to first transfusion in this hospital, so these results were not 112 
consulted prior to transfusion. 113 
 114 
Signalment, weight, blood type, whether WB or pRBCs were administered, age of pRBCs, 115 
PCV prior to transfusion and as close to 12 hours after the end of the transfusion, 116 
diagnosis, administration of additional RBC containing blood products and survival to 117 
discharge were recorded for the recipients.  Blood type, PCV and volume of donation were 118 
recorded for the donors.   119 
 8 
 120 
The recipient increase in PCV at 12 hours post donation was normalised relative to 121 
the amount of RBCs administered to the recipient cat and their bodyweight (ΔPCVnorm) 122 
using a novel formula:  123 
ΔPCVnorm = (PCVpost – PCVpre)   / ((BDV x PCVdonor) / Wtrecip) 124 
Where: 125 
 PCVpost: The PCV of the recipient at 12 hours after the end of the transfusion in % 126 
PCVpre : The PCV of the recipient prior to transfusion in %    127 
BDV : The blood donation volume in ml (without anticoagulant) 128 
PCVdonor : The PCV of the donor in % 129 
Wtrecip : The weight of the recipient in kg 130 
 131 
The recipient transfusion monitoring sheets (involving a minimum of hourly temperature, 132 
pulse and respiratory rate measurement) and kennel sheet medical records were 133 
reviewed to assess for the presence of a transfusion reaction.  As there are no current 134 
veterinary definitions for transfusion reactions human guidelines were adapted for the 135 
purposes of this study (NHSN, 2018).  Acute development of urticaria or pruritis during the 136 
transfusion was classified as an allergic reaction.  If a recipient had an increase in rectal 137 
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temperature of greater than 1°C from baseline at the beginning of the transfusion, non-138 
pathological reasons for the increase e.g. external warming, recovery from general 139 
anaesthesia were considered by the study authors on a case by case basis. If no such 140 
reason was found a HTR was diagnosed if there was evidence of haemolysis in plasma 141 
or urine or an otherwise unexplained increase in total bilirubin concentration post 142 
transfusion alongside a rapid decrease of PCV post transfusion (a HTR was also 143 
diagnosed if these factors were fulfilled without a pyrexia during the transfusion). If 144 
there was no evidence of a HTR, cytological examination of the blood product was 145 
performed to assess for the presence of bacteria and the blood product date and 146 
appearance were checked.   If abnormalities were noted, or if the pyrexia did not 147 
spontaneously resolve after cessation of blood product administration, a suspected septic 148 
transfusion was recorded and a culture of the blood product was performed.  If neither a 149 
septic nor a HTR were suspected then a FNHTR was recorded.  Transfusion associated 150 
circulatory overload (TACO) was recorded if a cat developed respiratory distress (defined 151 
as increased effort and tachypnoea) or novel pleural fluid or radiographic changes 152 
consistent within volume overload within 24 hours of the transfusion alongside 153 
echocardiographic changes compatible with volume overload or if the patient was treated 154 
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with furosemide. Transfusion related acute lung injury (TRALI) was recorded if the 155 
recipient developed acute respiratory distress within 24 hours of the transfusion, with 156 
radiographic or computed tomography evidence of bilateral pulmonary infiltrates and no 157 
evidence of congestive heart failure on echocardiography.   158 
 159 
Age, recipient PCV before and after transfusion, and ΔPCVnorm were assessed for 160 
normality using a Shapiro–Wilk test.  Descriptive statistics were produced for the study 161 
population.  Concurrence between crossmatching techniques was assessed using Cohen’s 162 
unweighted Kappa. The mean/median ΔPCVnorm was calculated for all cats and separately 163 
for those cats which received pRBCs and WB and those with and without major 164 
crossmatch incompatibility results.  Results were then compared using a t-test or Mann–165 
Whitney U test as appropriate.   166 
 167 
The frequency and type of transfusion reactions in all cats and those in each crossmatch 168 
incompatible group were also calculated.  Rates of FNHTR and HTR for cats receiving 169 
pRBCs and WB and survival rates for cats that had transfusion reactions were compared to 170 




Recipient population 174 
One hundred and one cats were recruited to the study between May 2016 and September 175 
2018, with an extra cat being recruited before it was noted that a sufficient number had 176 
been reached.  There were 45 female neutered, 54 male neutered, and 2 female entire 177 
cats.  There were 56 domestic short hair cats, 10 domestic long hair cats, 5 Persians, 5 178 
British short hairs, 4 Burmese, 4 Russian blues, 3 Bengals, 2 Siamese, 2 British blues and 1 179 
each of Abyssinian, Burmese cross, domestic medium hair, exotic short hair, Havana, 180 
Maine coon, Norwegian forest, ragdoll, Tonkinese and Turkish van breeds.  There were 87 181 
type A cats, 10 type B cats and 4 type AB cats. The median age was 81 months 182 
(interquartile range (IQR) 44-113 months). The patient’s underlying disease processes 183 
were classified as anaemia due to lack of RBC production (23 cats), RBC destruction (45 184 
cats) or loss of RBCs (33 cats). Sixty-five cats received pRBCs and 36 received fresh WB.  185 
Seventy-eight cats survived to discharge from the hospital, 17 were euthanased and 6 died 186 
during their hospitalisation period.  187 
 188 
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The median PCV prior to transfusion was 12% (IQR 9-15%) and after transfusion was 19% 189 
(IQR 15-21%).  A post transfusion PCV was not obtained for one cat as it was unstable and 190 
venepuncture was not possible prior to cardiopulmonary arrest which occurred 12.25 191 
hours after the end of the transfusion.  The median time the PCV was obtained after the 192 
end of the transfusion was 12 hours (IQR 10.5-13 hours).   193 
 194 
Crossmatch compatibility and PCV increase 195 
A high frequency  (27%) of major crossmatch incompatibility was found with the 196 
laboratory method with a lower frequency (10%) for the minor crossmatch laboratory 197 
method. Both major and minor crossmatch incompatibility was less frequent (both 4%) 198 
with the commercial test method (Table 1). Agreement between the laboratory and 199 
commercial crossmatching methods is shown in Tables 2 and 3.   Unweighted Kappa 200 
agreement between the methods was found to be poor for the major crossmatch  ((Kappa 201 
statistic 0.1351, 95% CI 0-0.5057, n=68) and fair for the minor crossmatch (Kappa statistic 202 
0.3645, 95% CI 0-0.9254, n=43) . The recipient control was reported to be agglutinating in 203 
18/96 cats (19%), and in 9 of these cases, the minor crossmatch was also agglutinating and 204 
was therefore deemed to be uninterpretable. The donor control was reported to be 205 
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agglutinating in 1/98 cats (1%) and in this case the major crossmatch was also 206 
agglutinating and was therefore deemed to be uninterpretable.  207 
 208 
The median ΔPCVnorm was 0.01279kg/ml (IQR 0.00567-0.02100).  The ΔPCVnorm did not 209 
differ significantly between cats receiving pRBCs (median 0.01207, IQR 0.00926-0.02248) 210 
and WB (median 0.01413, IQR 0.00509-0.01972) (p=0.24).  The ΔPCVnorm for major 211 
crossmatch compatible and incompatible blood for each test is shown in Table  4.  There 212 
were no significant differences between ΔPCVnorm for crossmatch compatible and 213 
crossmatch incompatible blood for either crossmatching method (table 4).  214 
 215 
Transfusion reactions and crossmatch compatibility 216 
Transfusion reactions occurred in 20/101 cats. Nine cats had FNHTRs, 7 cats had HTRs, 3 217 
cats had TACO, 2 developed hypothermia during their transfusion and 1 cat had a 218 
transfusion transmitted infection (the cat was transfused with Mycoplasma 219 
haemominutium positive blood and was found be PCR positive for the organism post 220 
transfusion).  Although all feline donors are checked for feline Mycoplasma spp, the result 221 
was not available prior to transfusion as this was an emergency fresh WB transfusion to 222 
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the recipient. Complications occurred in 2 transfusions. One cat was administered 223 
approximately 10-15 mL of her transfusion subcutaneously due to intravenous cannula 224 
displacement. One cat was initially typed as an AB cat and was administered type A pRBCs 225 
due to a lack of immediate type AB blood availability.  The cat had a HTR and on repeat 226 
blood typing, it was found that the cat was actually blood type B. Both the laboratory and 227 
commercial test major crossmatches were incompatible with both minor crossmatches 228 
compatible for this cat as would be expected.   229 
 230 
Seven/65 ((11%) cats receiving pRBCs had a FNHTR compared to 2/36 (6%) cats receiving 231 
WB.  Five/65 (8%) cats receiving pRBCs had a HTR compared to 2/36 (6%) receiving WB.  232 
These proportions were not significantly different. 233 
 234 
The laboratory crossmatch suggested incompatibility for 3/7 (43%) cats that had a HTR (2 235 
cats had major crossmatch incompatibility and one had both major and minor 236 
incompatibly); this compared to an incompatibility rate of 30/90 (33%) for cats that did 237 
not have a HTR.  The commercial test crossmatch suggested incompatibility in 2/4 (50%) 238 
cats (one major crossmatch incompatibility and one minor crossmatch incompatibility) 239 
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compared to 2/68 (3%) that did not have a HTR. The 2 HTR cats that did not have 240 
incompatibility noted by the commercial test did not have minor crossmatches performed 241 
with this method.  242 
 243 
Of the 9 cats with FNHTRs, the laboratory major crossmatch suggested incompatibility for 244 
2 cats and the laboratory minor crossmatch suggested incompatibility for no cats.  The 245 
commercial test was used in 7 of the FNHTR cats and all major and minor crossmatches 246 
were compatible for these cats.  247 
 248 
Recipient outcome 249 
Nineteen cats had at least one further WB or pRBC transfusion after their first transfusion. 250 
Two of the 6 cats (33%) that had a HTR required a further transfusion compared to 15 of 251 
the 92 (16%) cats that did not.  This was not statistically significantly different.  Survival to 252 
discharge was 66% for cats that had a HTR compared to 78% in cats that did not and 89% 253 
for cats that had a FNHTR compared to 76% in cats that did not (neither difference was 254 




The first and second aims of this study were to determine the frequency of crossmatch 258 
incompatibility in cats which had not previously been administered a blood product and to 259 
compare the results of two crossmatching methods. It was shown that the frequency 260 
differed markedly between the two techniques studied, with a relatively high level of 261 
crossmatch incompatibility reported using a laboratory method and a much lower level of 262 
incompatibility reported using the commercial test.  This finding concurs with an 263 
investigation comparing a laboratory method with the same commercial test used in this 264 
study in dogs (Guzman et al 2016).  In that study it was concluded that the commercial 265 
test was inaccurate, but in this study, the clinical follow up of the crossmatched cats 266 
suggest that the laboratory method may actually be the less useful method as 267 
incompatibility was not associated with a detectable HTR in most cases.  Guzman et al 268 
(2016) noted that interpretation of the commercial test could be difficult and it should be 269 
noted that in this study a simplified approach to identification of an incompatible 270 
crossmatch result was used which differs slightly from that recommended by the 271 
manufacturers.   Other studies looking at major crossmatching in cats prior to first 272 
transfusion report report similar incompatibility rates between 14.9 and 17% (McCloskey 273 
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et al 2018, Sylvane et al 2018, Weltmand et al 2014) between the laboratory rate of 27% 274 
and the commercial test rate of 4% reported here.  275 
 276 
The Kappa agreement between the crossmatching methods was very poor, suggesting 277 
they are not interchangeable.  There are very wide confidence intervals for the Kappa 278 
agreement due to the relatively low overall number of cases when both crossmatching 279 
methods were used and the lower level of incompatibility reported by the commercial 280 
test.  281 
 282 
 283 
Our third aim was to assess the effect of crossmatch incompatibility on the change in PCV 284 
seen post-blood donation. We found that administration of crossmatch incompatible 285 
blood in transfusion naïve cats was not associated with a lower retention of RBCs at 12 286 
hours when compared to administration of crossmatch compatible blood (for both 287 
method of crossmatching).  However, it could be argued that sampling PCV at 12 hours 288 
may have been too early to detect the effects of a HTR, and the fall in PCV may occur 289 
later.  Weingart et al (2004), in a large retrospective study, described several cats that had 290 
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clinical signs consistent with HTRs when their total bilirubin concentrations increased 1-5 291 
days after transfusion and their PCV rise was lower than expected at 16-24 hours post 292 
transfusion.  Similarly, a Mik-negative cat administered presumed Mik-positive blood was 293 
described to have an increase in serum bilirubin and haemoglobinemia 24-48 hours post 294 
transfusion (Weinstein et al, 2007).  It was therefore important that this study monitored 295 
the progression of the cats throughout their hospitalisation time and assessed them for a 296 
HTR which may not have been noted by assessing PCV at the 12-hour mark. 297 
 298 
The commercial test found incompatibility in 2/4 HTR cases.   Although not all HTRs were 299 
detected by this method of crossmatching, this may at least in part have been because 300 
minor crossmatches were not performed in the 2 cats where no incompatibility was 301 
detected.  This study suggests that as a minimum, the commercial test may be a useful 302 
method for assessing compatibility. If this test suggests compatibility, then a HTR is 303 
unlikely.  The laboratory crossmatch method did not appear as useful in the detection of 304 
HTR patients where 43% of the cats had either major or minor (or both) crossmatch 305 




Several reasons can be postulated as to why the laboratory method was not reliable for 309 
the prediction of HTRs in transfusion naive cats.  Firstly, the method is subjective, and 310 
although technicians were trained in assessment for agglutination, human error is possible 311 
(Abrams-Ogg, 2016). Secondly a large proportion of the cats in the study had immune 312 
mediated haemolytic anaemia and many had spontaneous agglutination. The laboratory 313 
method included cell washing, but agglutination is still possible after this procedure.  314 
Finally, it is possible that the laboratory method was detecting incompatibilities that were 315 
present, but that were not clinically relevant and did not result in an appreciable HTR.  316 
 317 
Although crossmatch incompatibility would suggest a HTR was more likely rather than any 318 
other transfusion reaction , FNHTR were also examined in this study as McClosky et al 319 
(2018) found that FNHTR were more common in their non-crossmatched cats compared 320 
to their group administered crossmatch compatible blood.  This was not the case in this 321 
study, with low levels of incompatibility with both crossmatching methods noted for cats 322 
that had FNHTRs.  It is possible that in the McClosky et al (2018) study, the patients 323 
classified as having FNHTR may have actually been having HTRs and this was hard to 324 
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detect given the retrospective nature of the study.  It is probably important to note that 325 
primary clinicians caring for the patients in this study did not always recognise the 326 
occurrence of a transfusion reaction as clinical signs were sometimes mild in nature.  327 
 328 
 329 
The final aim of the study was to assess the frequency of transfusion reactions and 330 
complications and errors.  The frequency of transfusion reactions in this population was 331 
high at approximately 1 in 5 cats.  It is much higher than that reported in several previous 332 
studies (Castellanos et al 2004; McClosky et al 2018; Weingart et al 2004).  A study in dogs 333 
reported a much higher transfusion reaction rate of 15% with reactions being more 334 
common with pRBC transfusions compared to other blood products (Bruce et al 2015). In 335 
people, transfusion reactions are well defined and rates of between 0.2 and 3.8% have 336 
been reported, with variation between studies and blood products administered (Kato et 337 
al 2013; Kato et al 2015; Negi et al 2015). 338 
However veterinary studies reporting transfusion reactions are hampered by the lack of 339 
clear guidelines of what constitutes an transfusion reaction.  Also, this was a prospective 340 
study where the cats were specifically being monitored for transfusion reactions and so it 341 
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is likely that cases were recorded which could otherwise have been missed. This is 342 
especially true for HTRs, where close monitoring was required to detect the increase in 343 
serum bilirubin as this was often not marked and often did not result in clinical icterus.  344 
The transfusion reaction rate in this study is similar to that described in another 345 
prospective study where a frequency of 23% transfusion reaction was noted, with the 346 
majority being FNHTR, as with this study (Sylvane et al 2018). 347 
 348 
HTRs are classified as acute if they result from pre-formed antibodies and delayed if the 349 
antibodies develop post transfusion (Strobel 2008).  In this study it is suspected that the 350 
HTRs noted were acute.  Although only one of the cats developed pyrexia during the 351 
transfusion, in all cases evidence of haemolysis occurred with 24 hours, when signs of a 352 
delayed HTR are expected after 24 hours (National Healthcare Safety Network 2018).  This 353 
suggests that pre-formed non-AB antibodies, such as anti-Mik antibodies, were present in 354 
several cats in this study.  There was no difference in the need for further blood products 355 
or survival to discharge noted in the cats with a HTR however.  Although this does not 356 
mean that the cats with a HTR had no difference in morbidity when compared to those 357 
without, it does suggest that the effect was not marked.  358 
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 359 
Definitive proof that these were genuine transfusion reactions was not possible to obtain 360 
given the clinical nature of the study.  Even the transfusion-transmitted infection case 361 
with the administration of blood from a Mycoplasma haemominutium infected donor was 362 
not a definite transfusion reaction, as the recipient was not assessed for the presence of 363 
the organism prior to transfusion. Ideally, to confirm a patient had a HTR, a direct 364 
antiglobulin test should be performed both before and after the transfusion to assess for 365 
the presence of anti-erythrocyte antibodies and whether there is an increased reaction 366 
post transfusion as in human medicine (Strobel 2008).  The diagnosis of FNHTR is made by 367 
discounting all other possible causes of pyrexia, which was attempted during the study, 368 
but it is possible that HTRs could have been misdiagnosed as FNHTR if they were mild 369 
although most of the HTRs in this study were not associated with a pyrexia.  It is difficult in 370 
the clinical situation to state that development of hypothermia or respiratory distress is 371 
definitely secondary to transfusion given the multitude of other treatments being 372 
administered in these critical patients.  However, the guidelines, based on human 373 
guidelines for the diagnosis of transfusion reactions, described in the methods were used 374 
to maximise the likelihood of genuine diagnosis.   375 
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 376 
This study has many limitations.  Firstly, there was insufficient data in the literature when 377 
the study was planned to perform a sample size calculation to determine the number of 378 
cases. Moreover, this study was aimed at assessing the agreement in performance of 2 379 
tests for the detection of a reaction, not to assess the frequency of a disease. In light of 380 
these issues, a convenience sample of 100 cats was chosen to provide a sufficiently large 381 
population that we hoped would detect a difference if one was present and that was also 382 
achievable to allow recruitment over 2 years, but given the results obtained, it is likely the 383 
study was under-powered. Secondly, as noted above, the timing of blood sampling post 384 
transfusion may have been too early to detect the results of a HTR.  However, given the 385 
dynamic nature of many of these patients’ disease processes, leaving sampling too long 386 
may have meant it was difficult to assess the impact of the transfusion.  This clinical aspect 387 
of the trial is a strength, as it allows assessment of the impact of crossmatching and 388 
transfusion reactions in the clinical situation.  However, it also means the recipients were 389 
very variable, transfusion administration was not standardised and the impact of general 390 
anaesthesia, dehydration and volume status could all have affected the PCV alongside on-391 
going haemorrhage and RBC lysis depending on the underlying disease process. Also, 392 
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some patients died during or shortly after transfusion administration, meaning that 393 
possible transfusion reactions may have been missed.  Thirdly, sufficient blood to run each 394 
crossmatch was not available for each patient as they were often unstable prior to 395 
transfusion.  Therefore, a commercial test major crossmatch was only performed on 396 
approximately 2/3 of the study population and a commercial test minor crossmatch on 397 
approximately ½.  Only 2 methods of crossmatching were tested and other commercial 398 
and non-commercial methods are available which may have differing results. Finally, 399 
although every effort was made to monitor for transfusion reactions, they may have been 400 
missed as the clinical nature of the patients meant that treatment and blood sampling was 401 
not standardised. 402 
 403 
In summary, this study showed no advantage in crossmatching patients prior to first 404 
transfusion when assessing increase in PCV at 12 hours and survival to discharge which is 405 
consistent with the findings of previous large studies (McClosky et al 2018; Sylvane et al 406 
2018).   Interestingly, these studies have differing conclusions with Sylvane et al (2018) 407 
suggesting that their results do not support the use of crossmatching prior to first 408 
transfusion in cats, whereas McCloskey et al (2018) state that the prevalence of naturally 409 
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occurring non-AB incompatibilities they detected is sufficiently high to justify the 410 
recommendation to perform a crossmatch prior to first RBC transfusions in cats.  Our 411 
study has found that cats can have a HTR on first transfusion and that this is not 412 
uncommon.  Although the laboratory method seems less useful at predicting these, when 413 
the commercial test suggests incompatibility, a HTR appears to be more likely.  Although a 414 
negative impact of HTR could not be demonstrated in this study, that could be due to low 415 
case numbers and lack of sufficient monitoring.  Ultimately, in the authors’ opinion, a 416 
pragmatic approach is probably best.  It could be argued that if there are multiple donors 417 
available, then crossmatching prior to first transfusion, and use of a compatible donor is 418 
optimal, although if this is not feasible, this study suggests that transfusion without prior 419 
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